Expert Interview
A look at the topline results from the Phase 3 CREST trial of Pfizer's sasanlimab in combination with BCG for patients with high-risk non-muscle invasive bladder cancer.
Ticker(s): PFEInstitution: Urology Associates, P.C
- Co-director of Urologic Associates, P.C and Clinical Associate Professor of Urology at Vanderbilt
- Treats 500 NMIBC patients per year
- Clinical and Research interest in immunotherapy and novel therapies for patients with complex urinary tract cancers and has experience with kidney, prostate, and bladder surgery with an emphasis on minimally-invasive cancer surgery.
Can you talk about the current treatment landscape and what therapeutics you utilize?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of sasanlimab, what would it be and why?
Added By: sara_adminRoughly how many patients do you treat with BCG-naïve, high-risk NMIBC per year?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
